J. Goldman & Co’s Immunovant IMVT Stock Holding History

J. Goldman & Co’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-21,000	Closed	-$359K	–	540
2025 Q1	$359K	Sell	21,000 -13,337	-39%	-$279K	0.01%	416
2024 Q4	$851K	Buy	+34,337	New	+$974K	0.02%	339
2019 Q4	–	Sell	-300,000	Closed	-$3.01M	–	307
2019 Q3	$3.01M	Buy	+300,000	New	+$2.96M	0.23%	121

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

J. Goldman & Co's IMVT Position: Q2 2025 in Review

J. Goldman & Co sold out of Immunovant (IMVT) in Q2 2025, closing a stake of 21,000 shares — an estimated $359K sold.

J. Goldman & Co first reported a position in IMVT in Q3 2019 and held it in 3 quarters. The position peaked at $3.01M in Q3 2019. 168 funds tracked by Wall St. Rank hold IMVT as of Q2 2025.

J. Goldman & Co reported no remaining Immunovant position as of Q2 2025 after selling out during the quarter.
J. Goldman & Co sold 21,000 Immunovant shares in Q2 2025, an estimated $359K.
J. Goldman & Co first reported a position in Immunovant in Q3 2019 and held it in 3 quarters.
J. Goldman & Co's Immunovant position peaked at $3.01M in Q3 2019.
168 funds tracked by Wall St. Rank held Immunovant as of Q2 2025.

Based on J. Goldman & Co's 13F filing for Q2 2025, filed 14 Aug 2025.